[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Center for International Blood and Marrow Transplant Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":240},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,84,120,152,179,201,221],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100636232","phase-2-menin-inhibitor-targeted-maintenance-in-aml-100636232",false,"NCT07563010","Menin-Inhibitor Targeted Maintenance in AML","Phase 2 Randomized Controlled Study of Revumenib as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With KMT2Ar, NPM1m, or NUP98r Acute Myeloid Leukemia (AML)","Inclusion Criteria:\n\nInclusion Criteria:\n\n1. Aged ≥18 years at the time of signing informed consent\n2. Able to provide written informed consent personally or via a legally authorized representative in accordance with applicable regulatory and institutional requirements\n3. Willing and able to comply with all study procedures and available for the duration of the study\n4. Diagnosis of acute myeloid leukemia (AML) in complete morphologic remission with one of the following molecular abnormalities:\n\n1\\. KMT2A-rearranged (KMT2Ar) AML (Excluding KMT2A partial tandem duplication (KMT2A-PTD) 2. NPM1-mutated (NPM1m) AML (Including FLT3-ITD or TKD co-mutation) 3. NUP98-rearranged (NUP98r) AML 5. Planned first allogeneic hematopoietic cell transplantation (allo-HCT) for AML.\n\n6\\. Transplant Characteristics\n\n1. Planned allo-HCT using bone marrow or peripheral blood stem cell graft source.\n2. Planned reduced-intensity\u002Fnon-myeloablative conditioning (RIC\u002FNMA) or myeloablative conditioning (MAC), using a conditioning regimen permitted- by the protocol and consistent with standard clinical practice, meeting CIBMTR criteria for conditioning intensity\n\n7\\. Planned donor:\n\n1. HLA-matched related donor (5\u002F6 or 6\u002F6)\n2. Matched unrelated donor (8\u002F8)\n3. Mismatched unrelated donor (7\u002F8)\n4. Haploidentical donor meeting institutional requirements\n\n8\\. Performance Status:\n\n1\\. Karnofsky Performance Status ≥70%. 9. Cardiac Function: left ventricular ejection fraction (LVEF) by transthoracic echocardiogram (TTE) or multigated acquisition (MUGA) with no clinical evidence of heart failure: RIC\u002FNMA: ≥50% MAC: ≥5 10. Pulmonary function meeting the following criteria, without supplemental oxygen other than CPAP:\n\n1. RIC\u002FNMA: DLCO (corrected for hemoglobin) and FEV1 ≥40% predicted\n2. MAC: DLCO and FEV1 ≥50% predicted\n\n11\\. Renal Function: estimated creatinine clearance (CrCl) ≥45mL\u002Fmin calculated using the Cockcroft-Gault formula or 24-hour urine collection, consistent with standard eligibility criteria for allogeneic HCT recipients.\n\n12\\. Liver function acceptable per local institutional guidelines for allo-HCT eligibility.\n\n13\\. Reproductive Status: Willingness to use contraception in accordance with local regulations from first study intervention through the required contraceptive period Willingness to use contraception in accordance with local regulations from first study intervention through the required contraceptive period\n\nExclusion Criteria:\n\n1. Disease Status:\n\n   a. Evidence of active AML prior to HCT, assessed within 42 days before transplant, defined as any of the following:\n   * ≥5% bone marrow blasts\n   * Circulating blasts within 14 days before conditioning\n   * CNS or other extramedullary disease\n2. Other active malignancy that, in the investigator's judgment, could interfere with safety or efficacy assessment\n3. Treatment with non-protocol antileukemic therapy (donor lymphocyte infusion for relapse prophylaxis or treatment will be considered an EFS event)\n4. Cardiac \u002F QT Risk\n\n   1. Requirement for concomitant medications known to prolong QT\u002FQTc interval, except low-risk agents used as standard supportive care\n   2. Diagnosis or suspicion of Long QT syndrome, or a family history of Long QT syndrome\n   3. Fridericia's corrected QT interval (QTcF) \\>450 msec.\n   4. History within 6 months of study entry of:\n\n   i. Myocardial infarction ii. Unstable angina iii. Congestive heart failure (NYHA Class ≥ II) iv. Life-threatening or uncontrolled arrhythmia v. Cerebrovascular accident or transient ischemic attack\n5. Chronic respiratory disease requiring continuous supplemental oxygen, or other significant organ dysfunction that would adversely affect study participation.\n6. Active, uncontrolled infection, including any of the following:\n\n   1. Active, uncontrolled systemic fungal, bacterial, or viral infection within 14 days prior to the start of conditioning\n   2. Any other documented active, uncontrolled infection at the start of conditioning\n7. Chronic viral infections with evidence of active disease, including:\n\n   HIV: detectable viral load within 6 months prior to screening\n\n   Hepatitis B:\n   * HBsAg-positive and\u002For anti-HBc-positive with detectable HBV DNA\n   * Anti-HBc-positive alone Hepatitis C: positive HCV antibody with detectable HCV RNA\n8. Planned HCT using cord blood, ex vivo T cell depletion, engineered grafts, or experimental graft sources\n9. Malabsorption syndrome or GI condition that precludes oral administration, including:\n\n   1. Inability to swallow oral medications\n   2. Prior gastric bypass or severe gastroparesis\n   3. Cirrhosis with Child-Pugh Class B or C\n10. Pregnant or breastfeeding\n11. Prior intolerance to menin inhibitor therapy resulting in ≥ Grade 3 treatment-related adverse events\n12. Any condition, therapy, laboratory abnormality, or allergy to excipients that, in the investigator's judgment, could confound study results, interfere with the participant's ability to comply with study procedures or complete the study, or make participation not in the participant's best interest.","ALL","18 Years",{"count":19,"type":20},146,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML. In addition to suppressing leukemogenic transcriptional programs and promoting leukemic differentiation, menin inhibition has been shown to modulate epigenetic states linked to antigen presentation and immune recognition. These properties provide a strong biological rationale for evaluating revumenib as maintenance therapy following alloHCT, with the goal of suppressing residual leukemic clones while preserving or enhancing GVL activity during immune reconstitution.",[26,27,28,29],"Relapsed Adult AML","Stem Cell Transplant Complications","Acute Myeloid Leukemia","Transplant-Related Hematologic Malignancy",[31,32],"Allogenic Transplant","post-transplant relapse prevention","NOT_YET_RECRUITING","2026-06-16",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":20},"2026-12",{"date":41,"type":20},"2031-06",{"name":43,"class":44},"Center for International Blood and Marrow Transplant Research","NETWORK",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100159702","a-multicenter-access-and-distribution-protocol-for-unlicensed-cryopreserved-cord-blood-units-cbus-100159702","NCT01351545","A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)","A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications","Inclusion Criteria:\n\n* Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment\n* Signed informed consent (and signed assent, if applicable) obtained prior to study enrollment\n* Pediatric and adult patients of any age\n\nExclusion Criteria:\n\n* Patients who are receiving only licensed CBUs\n* Cord blood transplant recipients at international transplant centers\n* Patients who are enrolled on another IND protocol to access the unlicensed CBU(s)\n* Patients whose selected unlicensed CBU(s) will be more than minimally manipulated",{"count":53,"type":20},99999,"OBSERVATIONAL","This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.",[57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73],"Hematologic Malignancies","Inherited Disorders of Metabolism","Inherited Abnormalities of Platelets","Histiocytic Disorders","Acute Myelogenous Leukemia (AML or ANLL)","Acute Lymphoblastic Leukemia (ALL)","Other Acute Leukemia","Chronic Myelogenous Leukemia (CML)","Myelodysplastic (MDS) \u002F Myeloproliferative (MPN) Diseases","Other Leukemia","Hodgkin Lymphoma","Non-hodgkin Lymphoma","Multiple Myeloma\u002F Plasma Cell Disorder (PCD)","Inherited Abnormalities of Erythrocyte Differentiation or Function","Disorders of the Immune System","Autoimmune Diseases","Severe Aplastic Anemia","RECRUITING","2026-06-02",{"date":77,"type":37},"2026-06-04",{"date":79,"type":4},"2011-10",{"date":81,"type":20},"2041-10",{"name":43,"class":44},142,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":108,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},"100582139","phase-2-a-platform-protocol-to-investigate-post-transplant-cyclophosphamide-based-graft-versus-host-disease-prophylaxis-in-patients-with-hematologic-malignancies-undergoing-mismatched-unrelated-donor-peripheral-blood-stem-cell-transplantation-100582139","NCT06859424","A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","ACCELERATE","Inclusion Criteria, MAC RECIPIENTS:\n\n1. Age 18 to \\\u003C 66 years (chemotherapy-based conditioning) or \\\u003C 61 years (TBI-based conditioning) at the time of signing informed consent\n2. Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and institutional requirements\n3. Stated willingness to comply with all study procedures and availability for the duration of the study\n4. Planned MAC regimen (see Table 8 in Section 7.4 for allowed MAC regimens)\n5. Available partially HLA-MMUD (4\u002F8-7\u002F8 at HLA-A, -B, -C, and -DRB1 is required) with age 16-35\n6. Product planned for infusion is MMUD T-cell replete PBSC as allograft\n7. HCT-CI \\\u003C 5 (Appendix H - Hematopoietic Cell Transplant Comorbidity Index Scoring). The presence of prior malignancy will not be used to calculate HCT-CI for this trial, to allow for the inclusion of patients with secondary or therapy-related AML or MDS.\n8. One of the following diagnoses:\n\n   1. AML, ALL, or other acute leukemia in first remission or beyond with ≤ 5% marrow blasts and no circulating blasts or evidence of extramedullary disease. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.\n   2. Patients with MDS with no circulating blasts and with \\\u003C 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with \\\u003C 5% vs 5-10% blasts in MDS). Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.\n9. Cardiac function: Left ventricular ejection fraction ≥ 45% based on most recent echocardiogram or multi-gated acquisition scan (MUGA) results\n10. Estimated creatinine clearance ≥ 45mL\u002Fmin calculated by equation\n11. Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin ≥ 50% and forced expiratory volume in first second (FEV1) predicted ≥ 50% based on most recent PFT results\n12. Liver function acceptable per local institutional guidelines\n13. KPS of ≥ 70% (Appendix I - Performance Status)\n\nInclusion Criteria, RIC\u002FNMA RECIPIENTS:\n\n1. Age ≥ 18 years at the time of signing informed consent\n2. Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and local institutional requirements\n3. Stated willingness to comply with all study procedures and availability for the duration of the study\n4. Planned NMA\u002FRIC regimen (see\n5. Table 9 in Section 7.4 for allowed NMA\u002FRIC regimens)\n6. Available partially HLA-MMUD (4\u002F8-7\u002F8 at HLA-A, -B, -C, and -DRB1 is required) with age 16-35\n7. Product planned for infusion is MMUD T-cell replete PBSC allograft\n8. One of the following diagnoses:\n\n   1. Patients with acute leukemia or chronic myeloid leukemia (CML) with no circulating blasts, no evidence of extramedullary disease, and with \\\u003C 5% blasts in the bone marrow. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.\n   2. Patients with MDS with no circulating blasts and with \\\u003C 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with \\\u003C 5% vs 5-10% blasts in MDS.) Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.\n   3. Patients with chronic lymphocytic leukemia (CLL) or other leukemias (including prolymphocytic leukemia) with chemosensitive disease at time of transplantation.\n   4. Higher-risk chronic myelomonocytic leukemia (CMML) according to CMML-specific prognostic scoring system or high-risk MDS\u002Fmyeloproliferative neoplasms (MPN) not otherwise specified are eligible, provided there is no evidence of high-grade bone marrow fibrosis or massive splenomegaly at the time of enrollment.\n   5. Patients with lymphoma with chemosensitive disease at the time of transplantation.\n   6. Patients with primary myelofibrosis or myelofibrosis secondary to essential thrombocythemia, polycythemia vera or MDS with grade 4 fibrosis.\n9. Cardiac function: Left ventricular ejection fraction ≥ 40% based on most recent echocardiogram or MUGA results with no clinical evidence of heart failure\n10. Estimated creatinine clearance ≥ 45mL\u002Fmin calculated by equation\n11. Pulmonary function: DLCO corrected for hemoglobin ≥ 50% and FEV1 predicted ≥ 50% based on most recent PFT results\n12. Liver function acceptable per local institutional guidelines\n13. KPS of ≥ 60% (Appendix I - Performance Status)\n\nExclusion Criteria:\n\n1. Suitable HLA-matched related or 8\u002F8 high-resolution matched unrelated donor available\n2. Subject unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing\n3. Subjects with a prior allogeneic transplant\n4. Subjects with an autologous transplant within the past 3 months\n5. Subjects who are breastfeeding or pregnant\n6. Uncontrolled bacterial, viral or fungal infection at the time of the transplant preparative regimen\n7. Concurrent enrollment on a GVHD prevention clinical trial\n8. Subjects who undergo desensitization to reduce anti-donor HLA antibody levels prior to transplant\n9. Patients who are HIV-positive with persistently positive viral load. HIV-infected patients on effective anti-retroviral therapy (ART) with undetectable viral load within 6 months are eligible for this trial. Patients with well-controlled HIV are eligible provided resistance panels are negative, the patient is compliant with ART, and their disease remains well controlled.","66 Years",{"count":93,"type":20},358,[23],"The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination.\n\nParticipants will:\n\n* Receive the standard or new drug combination after transplant\n* Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients\n* Take surveys about physical and emotional well-being\n* Give blood and stool samples.",[97,98,99,100,101,102,103,104,105,106,107],"AML (Acute Myelogenous Leukemia)","Acute Lymphoid Leukemia (ALL)","Acute Leukemia (Category)","MDS (Myelodysplastic Syndrome)","CML (Chronic Myelogenous Leukemia)","CLL (Chronic Lymphocytic Leukemia)","Prolymphocyctic Leukemia","Chronic Myelomonocytic Leukemia (CMML)","Myeloproliferative Neoplasm (MPN)","Lymphoma","Myelofibrosis",[89,109,110],"ACCEL-001","ACCEL-002","2026-03-16",{"date":113,"type":37},"2026-03-17",{"date":115,"type":37},"2025-07-25",{"date":117,"type":20},"2028-06",{"name":43,"class":44},13,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":129,"conditions":130,"keywords":138,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},"100145560","cibmtr-research-database-100145560","NCT01166009","CIBMTR Research Database","Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","Eligibility to Participate in the Research Database\n\nRecipient Eligibility Criteria:\n\n* Any recipient of an unrelated or related donor or autologous HSC transplant in a CIBMTR center is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children.\n\nIndividual with Marrow Toxic Injury Eligibility Criteria:\n\n* Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Eligible individuals may have received supportive care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR.\n\nUnrelated Donor Eligibility Criteria:\n\n* All donors registered on the NMDP Registry who have been requested to donate a product for a recipient are eligible to participate in the Research Database.\n* All maternal cord blood donors are enrolled in the NMDP Cord Blood Bank Investigational New Drug (IND) protocol, and sign an informed consent document specific to that protocol. Data collected as part of the Cord Blood Bank protocol are included in the Research Database.",{"count":128,"type":20},99999999,"The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies.\n\nA secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries.\n\nObjectives:\n\nTo learn more about what makes stem cell transplants and cellular therapies work well such as:\n\n* Determine how well recipients recover from their transplants or cellular therapy;\n* Determine how recovery after a transplant or cellular therapy can be improved;\n* Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy;\n* Determine how access to transplant or cellular therapy for different groups of patients can be improved;\n* Determine how well donors recover from the collection procedures.",[131,132,133,134,135,136,137],"Autologous Stem Cell Transplantation","Allogeneic Stem Cell Transplantation","Solid Tumors","Blood Cancers","CAR-T","Gene Therapy","Non-malignant Disease",[139,140,141,142,136,135],"Data Collection","CIBMTR","NMDP","Stem Cell Transplantation","2025-08-07",{"date":145,"type":37},"2025-08-12",{"date":147,"type":4},"2002-07",{"date":149,"type":20},"2050-07",{"name":43,"class":44},2,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":159,"sex":16,"minAge":17,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":21,"phases":163,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},"100116748","phase-3-filgrastim-mobilized-stem-cells-for-transplantation-using-unrelated-donors-100116748","NCT00785525","Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors","Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors","Inclusion Criteria:\n\n1. PBSC donors must meet the same criteria as NMDP marrow donors. These criteria are set forth in the Donor Center Manual of Operations.\n2. Confirmatory pregnancy test must be performed within 15 days of collection and prior to the start of filgrastim administration; this may require more than one test to be performed.\n\nExclusion Criteria:\n\n1. Pregnancy or uninterruptible breastfeeding. Pregnancy is an absolute contraindication under this protocol. Women who are breastfeeding must be willing and able to interrupt breastfeeding during the administration of filgrastim and for two days following the final dose.\n2. Sensitivity to filgrastim or to E. coli-derived recombinant protein products.\n3. History of autoimmune disorders, including rheumatic diseases and thyroid disorders. Exception: As with bone marrow donations, donors with a history of thyroid disease who have undergone successful therapy may be suitable.\n4. History of deep vein thrombosis or pulmonary embolism.\n5. History of iritis or episcleritis.\n6. Thrombocytopenia \\\u003C 150 x 10\\^9\u002FL (\\\u003C 150,000\u002FuL) at baseline evaluation.\n7. Current treatment with lithium. Drug interactions between filgrastim and lithium, which may potentiate the release of neutrophils, have not been fully evaluated.\n8. Positive Hemoglobin-Solubility (e.g., SickleDex or equivalent) test.\n9. Donors receiving experimental therapy or investigational agents.\n10. Positive pregnancy test collected\u002Freported prior to start of filgrastim.",true,"60 Years",{"count":162,"type":20},60000,[164],"PHASE3","The purpose of the study is to:\n\n* Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from National Marrow Donor Program donors (NMDP) donors\n* Assess the safety among NMDP donors of filgrastim administration and PBSC leukapheresis\n* Assess the safety and efficacy of filgrastim-mobilized PBSC in unrelated donor hematopoietic stem cell transplant recipients\n* Determine the acceptability of stem cell donation by filgrastim stimulated apheresis in normal donors",[167],"Healthy",[169],"Healthy Unrelated Stem Cell Donors","2025-04-09",{"date":172,"type":37},"2025-04-13",{"date":174,"type":37},"1997-02",{"date":176,"type":20},"2030-01",{"name":43,"class":44},4,{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},"100295579","assessment-of-allogeneic-hematopoietic-cell-transplantation-in-medicare-beneficiaries-with-multiple-myeloma-100295579","NCT03127761","Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma","Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)","Inclusion Criteria:\n\n* Medicare beneficiary\n* Stage II or III multiple myeloma and\u002For primary plasma cell leukemia\n* Eligible to receive an allogeneic HCT from any suitable allogeneic donor (as determined by the transplant center) including umbilical cord blood\n* Will receive allogeneic HCT at a US transplant center\n* Agree to submit comprehensive clinical data on their pre- and post-transplant clinical status and outcomes to the CIBMTR",{"count":187,"type":20},544,"Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity and mortality of this procedure historically limited its application in older patients.\n\nThus, although potentially curative, standard risk MM patients have excellent prognoses in the era of novel therapies which reduces the overall benefit of alloHCT. However, because the outcomes for high-risk MM remain poor despite the best available standard therapies (overall survival of 24-36 months), initial data suggest that alloHCT should be explored in this subset.",[190],"Multiple Myeloma",[190],"2023-08-29",{"date":194,"type":37},"2023-08-30",{"date":196,"type":37},"2017-07-25",{"date":198,"type":20},"2028-04",{"name":43,"class":44},1,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":207,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":210,"conditions":211,"keywords":212,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":200},"100280748","prospective-assessment-of-allogeneic-hematopoietic-cell-transplantation-in-patients-with-myelofibrosis-100280748","NCT02934477","Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis","Inclusion Criteria:\n\n* Patients fulfilling the following criteria will be eligible for inclusion in the study:\n\n  * PMF, post-ET MF, or post-PV MF.\n  * Int-2 or high-risk disease as determined by the DIPSS.\n  * Age ≥55 at the time of DIPSS assessment.\n  * For the alloHCT arm:\n\n    * Donors must be a 6\u002F6 HLA-matched related donors, defined by Class I (HLA-A and -B) intermediate resolution or high resolution DNA-based typing and Class II (HLA-DRBI) at high resolution DNA-based typing (but not monozygotic twins) OR an 8\u002F8 HLA-A, -B, -C, and -DRB1 at high resolution DNA-based typing matched unrelated donor identified through the National Marrow Donor Program (NMDP)\u002FBe The Match. Donors must meet institutional or NMDP\u002FBe The Match selection criteria; there is no age restriction for sibling donors.\n    * Both peripheral blood stem cells and bone marrow grafts are allowed.\n    * All conditioning regimen intensities are allowed.\n    * All GVHD prophylaxis regimens are allowed.\n  * Haploidentical donors are allowed in the Haploidentical Donor Study\n\nExclusion Criteria:\n\n* Patients with the following criteria will be ineligible for entry into the study:\n\n  * AlloHCT using umbilical cord blood unit(s) or HLA-mismatched adult donors (\\\u003C 6\u002F6 HLA alleles for related and \\\u003C 8\u002F8 HLA alleles for unrelated).\n  * Overlap syndromes.","55 Years",{"count":209,"type":20},650,"This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) using well-established CIBMTR report forms and data collection procedures as well as a study-specific supplemental form. Data on the historical non-HCT controls will be collected at 14 US academic centers. These centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.",[107],[107,213,214],"Hematopoietic Stem Cell Transplant","Medicare",{"date":194,"type":37},{"date":217,"type":4},"2016-11",{"date":219,"type":20},"2027-10",{"name":43,"class":44},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":200},"100433157","protocol-for-a-research-sample-repository-for-hematopoietic-cell-transplantation-other-cellular-therapies-and-marrow-toxic-injuries-100433157","NCT04920474","Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","Eligibility to participate in the Research Sample Repository Protocol:\n\nHematopoietic Cell (HC) or Other Cellular Therapy Donors\n\n* Donors are eligible to participate in the Research Sample Repository if they have donated or are scheduled to donate HCs or cellular therapy products to an allogeneic recipient either by a marrow harvest or by apheresis. This includes adults with and without decision making capacity and children.\n* All donors registered on the National Marrow Donor Program (NMDP) Registry, regardless of whether they have been requested to donate a product for a patient, are eligible to participate in the Research Sample Repository.\n\nCord Blood Units (CBUs)\n\n* Testable material from CBUs (Specimens) infused at treatment centers covered under the C. W. Bill Young Transplantation Program are eligible for inclusion in the Research Sample Repository. Material may be submitted by participating treatment centers, centralized laboratories and Cord Blood Banks.\n\nHematopoietic Cell Transplantation or Other Cellular Therapy Recipients\n\n* All U.S. recipients of allogeneic or autologous HC transplants or cellular therapies are eligible to participate in the Research Sample Repository. This includes adults with and without decision making capacity and children.\n\nPatients with Marrow Toxic Injury\n\n* Any patient who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Treatment Network (RITN) is eligible to participate in the Research Sample Repository. This includes adults with and without decision-making capacity and children.\n* Eligible patients may have received support care only, growth factor support, hematopoietic stem cell transplant or other appropriate medical treatment for marrow toxic injury",{"count":128,"type":20},"The primary purpose of the Research Sample Repository is to make blood samples available for research studies related to histocompatibility and hematopoietic cell transplantation (HCT) or other cellular therapy.\n\nRepresentatives of participating centers and investigators or research groups may request access to research samples contained in the Research Sample Repository for the purpose of conducting research including:\n\n* investigating molecular explanations for histocompatibility or clinical outcomes through analysis of genomic, epigenetic, or other biomolecular data\n* evaluating the factors that affect transplant or cellular therapy outcome\n* studying the distribution of HLA tissue types in different populations\n* studying the success of transplantation, cellular therapies or supportive care in the management of marrow toxic injuries\n* performing de-linked (anonymous) research",[131,132,230,231],"Cellular Therapy","Marrow Toxic Injury","2023-05-01",{"date":234,"type":37},"2023-05-03",{"date":236,"type":37},"1991-07",{"date":238,"type":20},"2030-07",{"name":43,"class":44},""]